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1. Resumo 
Durante as últimas décadas tem-se assistido a um aumento na incidência de cancro conjuntamente 
com uma melhoria na sobrevivência, resultando num número crescente de sobreviventes de 
cancro a nível mundial. Estes fatos sugerem a importância de se proceder a uma caraterização 
epidemiológica detalhada, em diferentes contextos demográficos, assim como efetuar uma 
monitorização frequente da evolução dos dados epidemiológicos. Neste contexto, a presente tese 
de doutoramento pretende contribuir para um melhor conhecimento da epidemiologia dos 
sobreviventes de cancro em Portugal durante a última década. De forma a atingir esse objectivo, 
foram desenvolvidos quatro trabalhos, com diferentes desenhos de estudo. Os parágrafos 
seguintes descrevem de forma resumida os objetivos específicos associados a cada um dos 
estudos, assim como a metodologia adotada e os resultados obtidos. 
a) Avaliar o estado de saúde e as condições socioeconómicas dos sobreviventes de cancro em 
Portugal, assim como a sua utilização de recursos de saúde (Artigo I) 
Comparou-se o estado de saúde, a utilização de recursos de saúde e as condições socioeconómicas 
entre os sobreviventes de cancro (CS) e a população em geral, utilizando dados de uma amostra 
representativa da população Portuguesa com idade ≥15 anos (n=35 229). Foram definidos três 
grupos de sobreviventes de cancro, de acordo com o tempo desde o diagnóstico e do último 
tratamento: CS1 – diagnóstico nos últimos 12 meses; CS2 – diagnóstico há mais de 12 meses e 
tratamentos nos últimos 12 meses; CS3 – diagnóstico e tratamento há mais de 12 meses. A 
comparação destes grupos com a população em geral foi ajustada para as variáveis idade, sexo e 
área de residência. 
A prevalência de CS foi de 2,2% (CS1: 0,2%; CS2: 0,9%; CS3: 1,1%). Verificou-se que os CS 
reportavam mais frequentemente um pior estado de saúde e incapacidade temporária, 
fundamentalmente nos grupos CS1 e CS2. Constataram-se níveis mais elevados de despesas de 
saúde e rendimentos familiares mais baixos nos estádios iniciais de sobrevivência da doença. A 
frequência de dificuldades financeiras reportadas foi superior nos indivíduos do sexo masculino 
pertencentes ao grupo CS3. 
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b) Comparar a frequência de exposição a factores de risco para doenças crónicas, entre 
sobreviventes de cancro e indivíduos sem antecedentes de neoplasia, utilizando uma coorte de 
base populacional Portuguesa (Artigo II) 
Com recurso a uma coorte de adultos, representativa da população da cidade do Porto 
(recrutamento: 1999-2003; seguimento de casos novos de cancro: até 2009), comparou-se, na 
avaliação inicial, a exposição ao tabaco e álcool, os hábitos alimentares e o nível de atividade física 
entre os seguintes grupos: a) sobreviventes de cancro (CS) – indivíduos com diagnóstico de cancro 
previamente à avaliação inicial (n=53); b) participantes sem cancro (NC) – indivíduos sem 
diagnóstico de cancro na avaliação inicial ou durante o seguimento (n=2261); c) participantes com 
cancro latente (LC) – indivíduos sem diagnóstico de cancro na avaliação inicial, mas com posterior 
diagnóstico durante o seguimento (n=139). 
A prevalência de fumadores activos foi de aproximadamente 20% entre os grupos CS e NC (média 
de consumo: 4 cigarros/dia) e de cerca de 30% no grupo LC (média de consumo: 7 cigarros/dia). 
Observou-se um consumo médio de álcool mais elevado no grupo LC (25,5 g/dia) e menor no 
grupo NC (17,0 g/dia). A proporção de indivíduos a praticar actividade física foi superior no grupo 
CS (≈50%), comparativamente com os grupos NC ou LC (≈33%). Os grupos CS e NC apresentaram 
níveis médios mais elevados de consumo de frutas e vegetais do que o grupo LC (4,2 e 4,4 vs. 3,8 
porções/dia). O nível médio de pontuação do índice integrado de comportamentos saudáveis 
(inclui tabagismo, actividade física e consumo de álcool, frutas e vegetais) foi mais elevado no 
grupo NC (1,74) e menor no grupo LC (1,52), enquanto no grupo CS foi de 1,63. 
 
c) Estimar a incidência de segundos tumores primários (SPC) numa coorte de base populacional 
de sobreviventes de cancro do norte de Portugal (Artigo III) 
Quantificou-se a taxa de incidência e a incidência cumulativa de SPC, assim como a razão de taxas 
de incidência padronizada (SIR), numa coorte de base populacional de indivíduos com o 
diagnóstico de um primeiro tumor primário (FPC) durante o período 2000-2003, utilizando dados 
do Registo Oncológico da Região Norte (RORENO). 
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Verificou-se uma taxa de incidência aproximadamente cinco vezes superior nos primeiros dois 
meses de seguimento (SPC síncronos), comparativamente com os restantes 58 meses (SPC 
metácronos), ao longo dos quais esta se manteve relativamente estável. Os sobreviventes de 
cancro revelaram uma taxa de incidência de cancro superior à população em geral (SIR=1,31; IC 
95%: 1,25-1,38), apesar das diferenças se atenuarem quando apenas se consideraram os SPC 
metácronos (SIR=1,02; IC 95%: 0,96-1,08). A taxa de incidência de cancro nas mulheres 
sobreviventes de cancro do pulmão foi superior ao observado na população em geral, enquanto 
nos sobreviventes de cancro da próstata se verificou o oposto. A incidência cumulativa aos cinco 
anos de SPC metácronos foi de cerca de 3%, atingindo valores próximos de 5% nos sobreviventes 
de FPC com risco menor de morte aos cinco anos. 
d) Quantificar e caracterizar os SPC identificados num grupo de casos incidentes de cancro do 
norte de Portugal e descrever a sua sobrevivência de acordo com as características do FPC 
(Artigo IV) 
Pretendeu-se quantificar a proporção de SPC entre os casos incidentes de cancro registados no 
RORENO durante o período 2000-2003 e descrever a sua sobrevivência com base na informação do 
estado vital em Dezembro de 2010. 
Identificaram-se 1607 SPC (3,8% do total de casos incidentes), sendo a proporção de síncronos de 
22,1%. As três topografias mais frequentes de SPC metácronos, assim como as respectivas 
topografias mais comuns de FPC foram: cólon (12,2%; FPC: próstata, mama e estômago), pulmão 
(10,5%; FPC: bexiga, estômago e cólon) e estômago (9.7%; FPC: próstata, mama e bexiga). A 
sobrevivência global aos cinco anos dos SPC metácronos foi de 47,4%; entre os subgrupos de alta 
(63,1%) e baixa sobrevivência (31,1%), não se verificaram diferenças estatisticamente significativas 
com base nas topografias dos FPC. 
Em conclusão, a frequência de sobreviventes de cancro em Portugal, conjuntamente com as suas 
co-morbilidades e constrangimentos socioeconómicos, constituem um importante de problema 
saúde com uma relevância cada vez maior no contexto nacional. Simultaneamente, os níveis 
elevados de exposição a factores de risco para doenças crónicas no grupo de sobreviventes de 
cancro, alertam para a necessidade de encetar esforços para reverter esta situação, tanto numa 
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dimensão clínica como no âmbito da saúde pública. O aumento do número de segundos tumores 
primários observado na última década, conjuntamente com taxas de incidência de cancro entre os 
CS superiores às observadas na população em geral, evidencia outra vertente igualmente relevante 
da carga de doença associada à crescente melhoria do prognóstico dos doentes com cancro.  
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2. Abstract 
The worldwide growing number of cancer survivors, due to the increase in cancer incidence along 
with better survival rates, highlights the health and socio-economic burden associated with 
survivorship. This demands an epidemiologic characterization within different settings, as well as a 
continuous monitoring of the evolving trends. Therefore, this thesis aimed to contribute to a better 
understanding of the epidemiology of cancer survivorship in Portugal, during the last decade. To 
accomplish this main goal, four studies were performed following different designs. The next 
paragraphs briefly describe the specific objective pursued in each study, as well as the 
methodology adopted and the main results. 
a) To assess cancer survivors’ health status, use of healthcare resources and socio-economic 
conditions, in Portugal (Paper I) 
We compared cancer survivors (CS) with the general population regarding health status, use of 
healthcare resources and socio-economic condition, using data from a representative sample of 
the Portuguese population aged ≥15 years (n=35 229). Three groups of CS were defined, according 
to the time since diagnosis and the latest cancer treatment: CS1 – diagnosis within 12 months of 
interview; CS2 – diagnosis more than 12 months before and treatment in the previous 12 months; 
CS3 – diagnosis and treatment more than 12 months before. These were compared with the 
general population, adjusting for differences in sex, age and place of residence. 
The prevalence of CS was 2.2% (CS1: 0.2%; CS2: 0.9%, CS3: 1.1%). Self-perceived health-status was 
worse among CS and short-time incapacity was more frequent among CS1 and CS2. Health 
expenses were higher in the early stages of survivorship. Lower household income and financial 
difficulties were more frequent in CS1 and CS3 men, respectively. 
b) To compare the frequency of exposure to environmental risk factors for chronic diseases 
between cancer survivors and individuals with no previous cancer diagnosis, within a Portuguese 
cohort (Paper II) 
In a cohort of adults (recruitment: 1999–2003; follow-up, through linkage with population-based 
cancer registry: up to 2009) from Porto, we compared the baseline exposure to smoking, alcohol 
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and dietary intake, as well as the physical activity level between: cancer survivors (CS) – cancer 
diagnosis before baseline (n=53); no-cancer participants (NC) – without cancer diagnosis at 
baseline or during follow-up (n=2261); latent cancer participants (LC) – participants with no cancer 
diagnosis at baseline but diagnosed during follow-up (n=139). 
The prevalence of current-smoking was nearly 20% among CS and NC (average consumption: 4 
cigarettes/day) and 30% in LC (average consumption: 7 cigarettes/day). LC had the highest average 
alcohol intake (25.5 g/day) and NC the lowest (17.0 g/day). The proportion of subjects reporting 
sports practice was higher for CS (≈50%) than for NC or LC (≈33%). CS and NC had higher 
fruit/vegetables consumptions than LC (mean number of servings/day: 4.2 and 4.4 vs. 3.8). In a 
composite index on health behaviors (including smoking, physical activity, and alcohol and 
fruit/vegetables intake) the highest and lowest average scores were observed in the NC (1.74) and 
LC (1.52) groups, respectively, whereas CS scored 1.63. 
c) To estimate the dynamics of SPC incidence in a population-based cohort of cancer survivors 
from North Portugal (Paper III) 
We quantified the incidence rate and cumulative incidence of second primary cancers (SPC) and 
standardized incidence ratios (SIR) in a population-based cohort of subjects diagnosed with a first 
primary cancer (FPC) during the 2000-2003 period (n=39451), using data from the Portuguese 
North Region Cancer Registry (RORENO). 
The incidence rate of SPC was more than 5-fold higher in the first two months of follow-up 
(synchronous SPC) than in the period between two months and five years (metachronous SPC), 
across which the incidence rates were relatively stable. Cancer survivors had an overall higher 
incidence rate of cancer than the general population (SIR=1.31; 95% CI: 1.25-1.38), although that 
difference faded when only metachronous SPC were considered (SIR=1.02; 95% CI: 0.96-1.08). 
Cancer incidence rates were higher among female lung FPC survivors and lower in prostate FPC 
cancer survivors than in the general population. The 5-year cumulative risk of developing a 
metachronous SPC was approximately 3%, and reached nearly 5% among patients with FPC 
associated with lower risk of death. 
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d) To quantify and characterize the SPC identified among the incident cancer cases from North 
Portugal, and to describe their survival according to the characteristics of the FPC (Paper IV) 
We aimed to quantify the proportion of SPC among the incident cases registered by the North 
Region Cancer Registry (RORENO) during 2000-2003, and to describe their survival using vital 
status at December 2010. 
A total of 1607 SPC (3.8% of all cancers) were registered (22.1% of synchronous). The most 
common metachronous SPC topographies and corresponding most frequent FPC were: colon 
(12.2%; FPC: prostate, breast and stomach), lung (10.5%; FPC: bladder, stomach and colon) and 
stomach (9.7%; FPC: prostate, breast and bladder). The overall 5-year survival of metachronous 
SPC was 47.4%; within the subgroups with higher (63.1%) and lower survival (31.1%) there were no 
significant differences across groups of FPC with expectably different survival. 
 
In conclusion, the frequency of cancer survivors in Portugal and their associated health and socio-
economic concerns are becoming increasing meaningful, as well as their exposure to chronic 
disease risk factors has still an ample scope for improving. Moreover, the incidence of SPC is higher 
than the cancer incidence in the general population, mainly in the first months of follow-up, 
constituting another relevant concern within the whole burden associated with the longer cancer 
survival. 
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3. Public Health relevance of cancer survivorship 
The increase in cancer incidence due to population aging [1, 2], the decline in cardiovascular 
mortality [3, 4] and higher levels of screening, concomitantly with improvements in cancer 
management strategies, resulted in a dramatic increase in the number of cancer survivors during 
the last decades [5, 6]. In 2012, there was an estimated worldwide population of approximately 32 
million cancer survivors [6] and the projections anticipate a 75% rise until 2030 [7]. As a result, the 
burden associated with cancer survivorship is growing, which includes the management of 
comorbidities and late effects of treatments [8, 9], the higher risk of developing a second primary 
cancer (SPC) [10], the social-economic consequences for the patient and for the society [11], as 
well as the financial concerns associated with the cost of care [12]. 
The health-status impairment and the socio-economic effects of cancer diagnosis and treatment 
are important concerns among the growing population of living persons ever diagnosed with 
cancer [8, 13]. Cancer survivors often suffer from persistent symptoms (pain, distress, fatigue or 
cognitive impairment), as well as employment changes and financial difficulties, that could affect 
not only the patient but also their families, among other short and long term effects [8, 13]. 
Assessing the impact of these phenomena in different settings is needed to support a more 
comprehensive management of oncological diseases. 
Cancer survivors also have a nearly 14% higher risk of developing a new malignancy than the 
general population [10]. SPC represented 6% of all incident cancer cases in Europe (1995-1999) 
[14] and 18% in the USA (2007) [15]; in some settings the proportion of SPC among all diagnosed 
tumors is estimated to be higher than breast, lung or prostate first primary cancers (FPC) [15]. The 
occurrence of SPC is mostly related to genetic characteristics, deleterious environmental exposures 
and late effects of FPC treatment [15, 16]. It is therefore important to characterize cancer survivors 
regarding the exposure to amendable risk factors such as treatment modalities of the FPC as well 
as lifestyle behaviors modifiable by health promotion activities like smoking, alcohol consumption, 
diet and physical inactivity [17-21]. On other hand, since SPC are a problem increasingly 
encountered in routine medical practice, descriptive data concerning the incidence of SPC should 
be available, to provide local clinicians with a benchmark to estimate the probability of cancer 
survivors developing another cancer within the next years. 
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These challenges, among others, contributed to the worldwide trend of increasing number of 
cancer survivorship research publications [13]. This represents a major change in the cancer 
research focus, which used to be centered on cure, to one including longer term issues such as 
morbidity and the quality of life of cancer survivors. Nevertheless, in Portugal, apart from the 
regular reports of the population-based cancer registries, the number of publications describing 
the several domains related to the burden of cancer survivorship is scarce. 
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Trends in cancer incidence, mortality and survival 
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4. Trends in cancer incidence, mortality and survival 
There is an increasing burden of non-communicable diseases, which nowadays are responsible for 
the majority of deaths worldwide, killing more people each year than all other causes combined 
[22]. Cancer is already the leading cause of death in many high-income countries and is expected 
to become a main cause of morbidity and mortality in the next few decades in every region of the 
world, irrespective of resource level [6]. 
 
4.1. Incidence and mortality 
4.1.1. Worldwide 
Worldwide, about 14.1 million new cancer cases and 8.2 million cancer deaths are estimated to 
have occurred in 2012. Forty-three percent of the new cancer cases and 35% of the cancer deaths 
occurred in the more developed regions. The overall estimated age-standardized incidence rate 
(ASR) of cancer was 182.3 cases per 100 000 persons per year (figure 1) [6]. It was almost 25% 
higher in men than in women, with rates of 205 and 165 per 100 000, respectively. Male incidence 
rates varied almost five-fold across the different regions of the world, with rates ranging from 79 
per 100 000 in Western Africa to 365 per 100 000 in Australia/New Zealand (with high rates of 
prostate cancer representing a significant driver of the latter) [6]. There was less variation in 
female incidence rates (almost three-fold) with rates ranging from 103 per 100 000 in South-
Central Asia to 295 per 100 000 in Northern America [6]. 
Regarding mortality, there was less regional variability than for incidence. The rates were 15% 
higher in more developed than in less developed regions among men, and 8% higher in women. In 
men, the rates were highest in Central and Eastern Europe (173 per 100 000) and lowest in 
Western Africa (69 per 100 000) [6]. In contrast, the highest rates in women were in Melanesia 
(119 per 100 000) and Eastern Africa (111 per 100 000), and the lowest in Central America (72 per 
100 000) and South-Central Asia (65 per 100 000) [6]. 
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Figure 1 – Worldwide distribution of estimated age-standardized cancer incidence rates (per 100 000 cases) in 2012 
 
Source: GLOBOCAN 2012 [6] 
Lung (13.0%), breast (11.9%), colorectum (9.7%), prostate (7.9%) and stomach (6.8%) tumors were 
the most frequent incident cancer cases, regarding worldwide data [6]. However, this distribution 
differed across the geographical regions; lifestyle-related cancers were more frequent in 
developed countries and the proportion of infection-related cancers was higher in developing 
countries, both for incidence and mortality (figure 2) [6]. 
The pattern of cancer incidence rates has been evolving during the last decades, showing a clear 
trend towards an increase of new cancer cases, both in developed and developing countries (figure 
3), although the estimates of age-standardized incidence rate (ASR) have been rising mainly in the 
developing countries (figure 4) [23]. 
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Figure 2 – Top ten incident cancers in developed and developing countries  
 
Data source: GLOBOCAN 2012 [6] 
The increase in the absolute number of cancer cases in the developed countries despite the stable 
ASR’s, mainly reflects the effect of population aging and the reduction in cardiovascular mortality  
[2, 3, 5]. Among developing countries, although the rapid societal and economic evolution 
contributed to reductions in infection-related cancers, they were offset by an increasing number of 
new cancer cases associated with tobacco consumption, diet, obesity and sedentary behaviors, 
showing a clear “epidemiologic transition” [7, 24]. Rising levels of screening at the population level 
might have also contributed to the increase of the cancer incidence burden in many settings, 
especially within those countries where the screening procedures used to be less frequent [7]. 
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Figure 3 – Trends in the absolute number of cancer cases (all sites, except non-melanoma skin cancer) in selected 
countries 
 
 
Source: CI-5 Plus [23] 
 
 
Figure 4 – Trends in age-standardized incident rate (world) of cancer (all sites, except non-melanoma skin cancer) in 
selected countries 
 
 
Source: CI-5 Plus [23] 
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Bray et al. [7], using worldwide data from GLOBOCAN and CI-5, evaluated the trends in age-
adjusted incidence rates of lung, female breast, colorectal, stomach, prostate, liver and cervical 
cancer, within the 1988–2002 period, stratified by sex, among 101 cancer registries from countries 
in medium, high or very high Human Development Index (HDI). A tendency towards increases in 
breast, colorectal and prostate cancers was observed in the very high HDI, high HDI and medium 
HDI regions. In very high HDI countries these trends seemed to be stronger, suggesting the 
contribution of high levels of cancer screening, and they might be indicative that an incidence 
plateau is closely to be reached, like it happened with colorectal cancer that stabilized or 
decreased its incidence rates in the last years. Among the high and medium HDI regions, the 
improvement in the social and economic conditions was accompanied by a rising prevalence of 
several reproductive, dietary, metabolic and hormonal risk factors (towards levels more similar to 
those commonly seen in very high HDI countries) which might have contributed to increase the 
incidence of those cancers [7]. Moreover, in some geographical areas with high or medium HDI, 
along with this westernization effect, the increasing levels of screening might have independently 
contributed to the observed rise in cancer incidence estimates [7]. 
Decreases in the incidence of stomach and cervical cancers were consistently seen in populations 
with very high, high and medium HDI levels. The reduction in cervical cancer burden has been 
attributed to the progressive lowering levels of HPV infection in older generations of women and, 
within higher-resource settings, the beneficial effects of mass screening cytology programs [7, 25]. 
The uniform reductions of stomach cancer incidence rates during the past 50 years were 
commonly endorsed to both a decline in the prevalence of Helicobacter pylori infection in 
successive birth cohorts related to changing childhood environment, and to improved food 
preservation practices and better nutrition [7, 25]. The onset of refrigeration for food transport 
and storage could have been vital in reduction of salt consumption by largely eradicating the need 
for salting, smoking, and pickling of foods [7, 25].  
Despite these worldwide evolving changes in the frequency of the different tumors, the overall 
burden of cancer is expected to continue rising. According to worldwide projections, there will be 
approximately 21.7 million new cancer cases (9.9 and 11.8 million, respectively among women and 
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men) in 2030, and the larger increases are anticipated to take place across the developing 
countries (figure 5).  
 
Figure 5 – Worldwide predictions of new cancer cases until 2030 
 
Data source: GLOBOCAN 2012 [6] 
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4.1.2. Portugal 
In Portugal, the estimated number of new cases of cancer and cancer deaths was 492 000 and 241 
000, respectively, corresponding to an age-standardized incidence rate of 246.2 cases per 100 000 
and an age-standardized mortality rate of 99.0 cases per 100 000 [6]. These estimates indicate that 
in Portugal, as in other developed countries, there is a high burden of disease related to cancer, 
especially among men (table 1). 
National data from the Portuguese population-based cancer registries, between 2001-2007, 
showed an increase from 33 052 (women: 15 026; men: 18 026) to 42 374 (women: 18 634; men: 
23 740) new cancer cases, as well as a trend of rising age-standardized incidence rates from 198.0 
(women: 173.9 per 100 000; men: 231.1 per 100 000) to 225.5 per 100 000 (women: 190.6 per 100 
000; men: 271.4 per 100 000). In North Portugal, although we can observe higher incidence rates, 
the trends were similar, showing an increase of age-standardized incidence rate from 211.5 
(women: 183.8 per 100 000; men: 250.9 per 100 000) to 249.0 per 100 000 (women: 190.6 per 100 
000; men: 271.4 per 100 000) (figure 6). 
 
Table 1 – Cancer incidence and mortality estimates for 2012 
Region 
Age-standardized rates, all ages (world reference population) 
Incidence rate/100 000 Mortality rate/100 000 
Women Men Women Men 
World 165.3 205.4 82.9 126.3 
Developed countries 240.6 308.7 86.2 138.0 
Developing countries 135.8 163.0 79.8 120.1 
Portugal 198.1 306.3 70.1 134.7 
 
Data source: GLOBOCAN 2012 [6] 
 
The trends of cancer incidence across the most frequent tumors also showed an increase during 
the same period (2001-2007), both in National [26-28] and North Portugal data [29-35], although 
with a stabilization or even a slight decrease in the more recent years. The more noticeable rises 
were observed among female breast and prostate cancers, possibly due to an increase in cancer 
screening (figure 6). 
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Figure 6 – Cancer incidence trends in Portugal: data from Portugal and North Portugal (RORENO) 
 
Data source: Portuguese National Cancer Registry [26-28] and North Region Cancer Registry (RORENO) [29-35] 
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4.2. Survival 
The worldwide heterogeneity of cancer incidence and mortality estimates is also observed for 
cancer survival. Coleman et al. [36] using data from the CONCORD project, provided the survival 
estimates for 1.9 million adults (aged 15–99 years) diagnosed with a first, primary, invasive cancer 
of the breast (women), colon, rectum or prostate during 1990–94, and followed up until 1999, 
across 31 countries on five continents, in a first attempt to directly compare cancer survival from 
many countries around the world. The study main findings showed that global variation in cancer 
survival was very wide. Five-year relative survival estimates [age-standardized for the International 
Cancer Survival Standard (ICSS) weights] for breast, colorectal and prostate cancer were generally 
higher in North America, Australia, Japan, and northern, western, and southern Europe, and lower 
in Algeria, Brazil and eastern Europe (figure 7). 
In Europe, over the past 20 years, EUROCARE studies have provided data showing that survival has 
improved, although at different paces depending of time analysis and geographical settings. The 
EUROCARE-5 study [37], the largest cooperative study of population-based cancer survival in 
Europe, using the more recent data from 107 cancer registries within 29 European countries (2000-
2007), revealed an overall age-standardized 5-year relative survival estimate of 54.2% (women: 
58.0%; men: 50.2%), ranging from 6.9% in pancreatic cancer (women: 7.9%; men: 6.3%) to 88.6% in 
testicular cancer. About a third of all cancer cases had a survival greater than 80%, whereas a 
quarter had survival below 30% [37].  
Survival in Eastern Europe was commonly lower and below the European mean, particularly for 
cancers with good or intermediate prognosis (such as prostate, female breast, rectum or non-
Hodgkin lymphoma). Survival was highest for northern, central, and southern Europe. 
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Figure 7 – Age-standardized [International Cancer Survival Standards (ICSS) population weights] 5-year relative survival for 
adults (aged 15–99 years) diagnosed with cancer of the breast, colorectum or prostate during 1990-94 and followed up to 
1999 
 
Reproduced from Coleman M et al. [36] 
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During the recent decades, cancer diagnosis and treatment have changed greatly. Cancer screening 
practices have been widely adopted, especially for breast, cervical, colorectal and prostate cancers, 
as well as early diagnosis initiatives to melanoma, thyroid and lung cancer have become frequent 
[38]. On other hand, there have been advances in diagnostic imaging, genetic profiling, and 
treatments, including the introduction of targeted drugs, multidisciplinary care, and a growing 
concentration of treatment in specialist centers [39-41]. As a result, the trends of cancer survival in 
Europe, considering data from EUROCARE-4 (1995-1999) and EUROCARE-5 studies (2000-2007), 
showed an overall increase of age-standardized 5-year relative survival from 50.4% to 53.2%. The 
trends within the EUROCARE-5 across the most frequent tumors showed a rise of age-standardized 
5-year relative survival, which was more noticeable in prostate, breast and rectal cancer survivors 
(figure 8) [37].  
Figure 8 – Trends in age-standardized (ICSS population weights) 5-year relative survival for adults (aged 15–99 years) 
diagnosed with cancer and followed up in the 1999–2001, 2002–04 and 2005–07 periods   
 
 Reproduced from De Angelis R et al. [37]  
The latest survival estimates from National Cancer Institute (NCI) in the USA, using data from SEER 
registries (2004-2010), showed a 5-year relative survival for all cancer sites of 68.3% (women: 
67.6%; men: 69.0%) [42]; in the past (1975-1977) the rates were lower [48.9% (women: 55.9%; 
men: 41.7%)], although a direct comparison between the two periods is limited since the rates 
were not age-standardized. 
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In Portugal, the 5-year age-standardized relative survival estimate (2000-2007) for all cancer sites 
was 56.4% (women: 60.8%; men: 52.1%) [37]. Data from North Portugal population-based cancer 
registry (RORENO) within the 2005-2006 period, revealed a 5-year age-standardized relative 
survival of 61.9% (women: 67.4%; men: 57.8%) [43].  
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5. Burden of cancer survivorship 
As previously described, during the last decades the number of new cancer patients has been 
increasing, mainly as a consequence of population growth, aging and screening; concurrently, the 
early diagnosis and more effective cancer treatments contributed to a better cancer survival 
leading to a growing number of cancer survivors, mostly in the more developed countries. 
Although these data reflect an improvement of healthcare in those settings, they also underline 
the growing burden of disease associated with cancer survivorship, especially regarding the 
management of comorbidities and late effects of cancer treatments, higher risk of developing a 
SPC and cost of care. 
 
5.1. Cancer survivors: definition and frequency 
The definition of cancer survivor has not been the same during the previous decades. In the past, 
cancer survivors used to be defined as those who remained disease-free for a minimum of 5 years 
[13]. In 1985, a publication in the New England Journal of Medicine by a young physician – Dr. 
Fitzhugh Mullan – describing his journey with cancer, revolutionized the concept of “cancer 
survivor”, proposing that any person should be considered a survivor from the time of diagnosis 
onward [44]. The National Cancer Institute (NCI) stated: “An individual is considered a cancer 
survivor from the time of diagnosis, through the balance of his or her life. Family members, friends 
and caregivers are also impacted by the survivorship experience and are therefore included in this 
definition” [13]. For statistical purposes, cancer survivors are prevalent cases and are often 
estimated by the 5-year cancer prevalence. However, since the latter is computed based on 
incidence and survival information of the population-based cancer registries [13] during the last 5 
years, it is expected that this measure underestimate the real prevalence of cancer survivors.  
Data from the GLOBOCAN 2012 [6] revealed an estimated 5-year prevalence of over 32.5 million 
cancer cases (women: 17.2 million cancer cases; men: 15.3 million cancer cases). Among the more 
developed countries there were 16.9 million cancer cases and 15.6 million were estimated within 
the developing countries [6]. The 5-year prevalence estimates for USA and Europe during the same 
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period were 4.7 and 9.8 million cancer cases, respectively; 134 300 cancer cases were estimated to 
be alive in Portugal in 2012 [6].  
However, to understand the overall burden of cancer survivorship, it is important to have 
information concerning other outcomes, apart from cancer frequency. Nowadays when more than 
half of cancer patients are expected to be alive after five years from the diagnosis, interest has 
grown in evaluating other domains, such as quality of life of cancer survivors and cancer-related 
sequelae that lead to disability. Therefore, information about fatal and non-fatal cancer-related 
outcomes is needed to aid establishing priorities in cancer control. Disability-adjusted life-years 
(DALYs) are a key measure for such purposes, since their two dimensions - years of life lost (YLLs) 
and years lived with disability (YLDs) - link the burden of cancer mortality with the degree of illness 
and disability in patients and long-term survivors [45]. 
Worldwide, more than 169 million healthy life-years were lost due to cancer in 2008, with 
differences across the several countries [45]. Colorectal, lung, breast, and prostate cancers were 
the most frequent contributors to total DALYs, being responsible for 18–50% of the overall 
estimates [45]. In sub-Saharan Africa and eastern Asia, respectively 25% and 27% of the total 
burden was associated with the infection-related cancers (liver, stomach and cervical) (figure 10).  
YLLs were the most important component of DALYs in all countries and for all cancers, contributing 
with more than 90% of the total burden [45]. Nonetheless, there were differences in the weight of 
YLLs as a proportion of DALYs across the different geographical settings, since higher rates of YLDs 
were observed in the more developed areas (figure 11), suggesting that the management of quality 
of life, disability and other late effects of cancer treatment is becoming increasingly relevant in 
these countries [45]. 
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Figure 10 – Age-adjusted DALYs by world region for the five cancers most frequent in each region  
 
DALYs=Disability-adjusted life-years; CNS - Central Nervous System 
Reproduced from Soerjomataram I et al. [45] 
 
Figure 11 – Age-adjusted DALYs per 100 000 population by cancer site and level of Health Development Index (HDI) 
 
 
DALYs=Disability-adjusted life-years; YLL=years of life lost; YLD=years of life lived with disability 
Adapted from Soerjomataram I et al. [45] 
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5.2. Health-status of cancer survivors 
The impact of cancer and cancer treatment on the short- and long-term health of cancer survivors 
is substantial. Late effects include not only the organ damage and functional disabilities that result 
from the disease, the treatment, or both, but also the development of second malignancies. 
Several psychosocial issues that adult cancer survivors have to face are also a matter of concern. 
 
5.2.1. Comorbidities 
The benefit of a longer life is offset for many survivors, by multiple persistent symptoms, including 
fatigue, distress, pain, and cognitive impairment [9, 13]. While some survivors remain on 
anticancer treatment and, thus, continue to experience treatment-related symptoms, others who 
have completed treatment will experience residual symptoms of both the disease and the 
treatment. In either case, symptoms cause a significant burden that diminishes their quality of life. 
More than 1 in 4 cancer survivors have high symptom burden one year after the diagnosis, even 
after treatment termination [9]. Metastatic cancer, the number of comorbid conditions, remaining 
on active chemotherapy, younger age, lacking of medical insurance, lower income, being 
unemployed and being less educated are some of the characteristics of the cancer survivors that 
had demonstrated to be associated with high symptom burden [9]. Depression, fatigue and pain 
constitute some of the complaints with greatest impact on health-related quality of life [9]. 
Beside the symptoms, that are more frequent in the first months of survivorship or during the 
active treatment phase, cancer survivors have a higher prevalence of chronic conditions compared 
to individuals without cancer [13]. These could be the result of long-term effects of cancer 
treatment or comorbid conditions not related to survivorship. 
 
Long-term cancer survivors are at risk for a variety of comorbidities, being the cardiovascular and 
pulmonary late effects some of the most frequent [46]. Chemotherapy-induced cardiovascular 
toxicity may include cardiomyopathy with or without overt congestive heart failure (CHF), 
endothelial dysfunction and arrhythmias [47]. Doxorubicin-induced cardiomyopathy is the most 
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studied chemotherapy-induced cardiovascular toxicity. A similar entity is associated with the 
anthracyclines and mitoxantrone and may also be associated with high-dose cyclophosphamide 
[47]. Radiotherapy-induced cardiovascular toxicity may include coronary artery disease (CAD), 
valvular disease, chronic pericardial disease, arrhythmias and conduction disturbances, 
cardiomyopathy or carotid artery stenosis [47]. 
Pulmonary toxicity may be secondary to either chemotherapy or radiotherapy; these toxicities can 
include radiation pneumonitis, pulmonary fibrosis and an overall decrease in pulmonary function 
[47]. Stem-cell transplantation may also be associated with long-term pulmonary complications, 
including idiopathic pneumonia syndrome and bronchiolitis obliterans [47]. Although a variety of 
chemotherapeutic agents may cause pulmonary toxicity, bleomycin has been the most studied. 
Of particular concern for cancer survivors are also the psychological side effects of cancer diagnosis 
and treatment. They often report cancer-specific concerns, such as fear of recurrence, as well as 
more generalized symptoms regarding their future, the possibility of death, trouble sleeping, 
fatigue and concentration difficulties [48]. Individuals with cancer may also experience a mental 
disorder or an exacerbation of a prior psychiatric disease (e.g. recurrent depression). Major 
depression and depressive symptoms occur frequently in cancer patients, and the prevalence 
varied from 10 to 25%, which was at least four times higher than the observed in the general 
population [13, 49]. 
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5.2.2. Second primary cancer 
Second primary cancers (SPC) have become an increasingly important concern in cancer 
epidemiology during the last two decades, as their proportion among the incident cancer cases is 
rising, comprising about 18% of all incident cases in the USA, superseding breast, lung and prostate 
first cancers [15, 50]. 
What was formerly a problem primarily in pediatric cancer survivors and for the survivors of the 
more curable adult cancers, has become a more universal concern in the practice of oncology 
nowadays. As previously addressed, the number of cancer survivors has steadily increased in the 
last decades due to advances in early detection, supportive care and treatment [5]. One of the 
most serious events those individuals can experience is the diagnosis of a new cancer – a SPC [10, 
15]. 
 
5.2.2.1. Definition of second primary cancers 
There are several definitions of SPC in the literature, all of them are around the concept that it 
should correspond to a second neoplasm that differs histologically or molecularly from the original 
cancer, not being a recurrence or a metastasis. Although the term “second primary cancers” is 
frequently used when considering multiple primary cancers (MPC), sometimes when more than 
two multiple primary cancers are observed in the same patient, only the second cancer is classified 
as a SPC [51]. The cancer registries worldwide mainly classify the SPC using the rules proposed by 
the International Association of Cancer Registries (IACR) and the International Agency for Research 
on Cancer (IARC) [52] or those defined by the Surveillance Epidemiology and End Results program 
(SEER).  
The IARC/IACR guidelines have the following recommendations: 
1. The recognition of the existence of two or more primary cancers does not depend on 
time;  
2. A primary cancer is one that originates in a primary site or tissue and is not an extension, 
nor a recurrence, nor a metastasis;  
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3. Only one tumor shall be recognized as arising in an organ or pair of organs or tissue. 
Some groups of codes are considered to be a single organ for the purposes of defining 
multiple tumors (these topography code groups are shown in table 2).  Multifocal 
tumours – that is, discrete masses apparently not in continuity with other primary 
cancers originating in the same primary site or tissue – are counted as a single cancer; 
4. Rule 3 does not apply in two circumstances: 
4.1. Systemic (or multicentric) cancers potentially involving many different organs are 
only counted once in any individual. These are Kaposi sarcoma and tumours of 
the haematopoietic system. 
4.2. Neoplasms of different morphology should be regarded as multiple cancers (even 
if they are diagnosed simultaneously in the same site). 
If the morphological diagnoses fall into one category in table 3, and arise in the same 
primary site, they are considered to be the same morphology for the purpose of 
counting multiple primaries. If the morphological diagnoses fall into two or more of the 
categories in table 3, even if they concern the same site, the morphology is considered 
to be different, and two or more cases should be counted. Single tumours containing 
several different histologies which fall into one histological group in table 3 are 
registered as a single case, using the numerically highest ICD-O morphology code.  If, 
however, one morphology is not specific [groups (5), (14) and (17)] and a specific 
morphology is available, the case should be reported with the specific histology and the 
non-specific diagnosis should be ignored. 
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Table 2 – Groups of topography codes considered a single site in the definition of SPC 
ICD-O-2/3 site code Label 
If diagnosed at different times, 
code first diagnosis. If diagnosed 
at the same time use codes 
given below 
C01  
C02 
Base of tongue 
Other and unspecified parts of tongue 
 
C02.9 
   
C00  
C03 
C04 
C05  
C06 
Lip 
Gum 
Floor of mouth 
Palate 
Other and unspecified parts of mouth 
 
 
 
 
C06.9 
   
C09  
C10  
C12  
C13  
C14 
 
Tonsil 
Oropharynx 
Pyriform sinus 
Hypopharynx 
Other and ill-defined sites in lip, oral 
cavity and pharynx 
 
 
 
 
C14.0 
   
C19  
C20  
Rectosigmoid junction 
Rectum 
 
C20.9 
   
C23  
C24  
 
Gallbladder 
Other and unspecified parts of biliary 
tract 
 
C24.9 
   
C33  
C34 
Trachea 
Bronchus and lung 
 
C34.9 
   
C40  
 
C41 
Bones, joints and articular cartilage of 
limbs 
Bones, joints and articular cartilage of 
other and unspecified sites 
 
 
C41.9 
   
C65  
C66  
C67  
C68  
Renal pelvis 
Ureter 
Bladder 
Other and unspecified urinary organs 
 
 
 
C68.9 
 
Adapted from “International rules for multiple primary cancers (ICD-0 third edition)”[52] 
SEER multiple primary coding rules are more liberal than IACR rules in allowing the registration of 
multiple primary cancers, particularly cancers that occur at the same site including paired organs 
(breast, kidney) and organs with relatively large surface areas (skin, urinary bladder, colon and 
rectum, oral cavity and pharynx) [53]. Therefore, based on SEER multiple primary rules, which are 
used by cancer registries in the United States and in the majority of provincial registries in Canada, 
the estimates of SPC tend to be systematically higher than if the IACR rules are applied [53]. 
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Table 3 – Groups of malignant neoplasms considered to be histologically ‘different’ for the purpose of defining SPC 
Group 
Carcinomas 
1. Squamous and transitional cell carcinoma  
2. Basal cell carcinomas  
3. Adenocarcinomas  
 
4. Other specific carcinomas  
 
5. Unspecified carcinomas (NOS)  
6. Sarcomas and soft tissue tumours  
 
7. Mesothelioma  
Tumours of haematopoietic and lymphoid tissues 
8. Myeloid  
 
9. B-cell neoplasms  
 
10. T-cell and NK-cell neoplasms  
11. Hodgkin lymphoma  
12. Mast-cell Tumours  
13. Histiocytes and Accessory Lymphoid cells  
14. Unspecified types  
 
15. Kaposi sarcoma  
16. Other specified types of cancer  
 
17. Unspecified types of cancer  
 
 
8051-8084, 8120-8131 
8090-8110 
8140-8149, 8160-8162, 8190-8221, 8260-8337, 8350-
8551, 8570-8576, 8940-8941 
8030-8046, 8150-8157, 8170-8180, 8230-8255, 8340-
8347, 8560-8562, 8580-8671 
8010-8015, 8020-8022, 8050 
8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-
9125, 9130-9136, 9141-9252, 9370-9373, 9540-9582 
9050-9055 
 
9840, 9861-9931, 9945-9946, 9950, 9961-9964, 9980-
9987 
9670-9699, 9728, 9731-9734, 9761- 9767, 9769, 9823-
9826, 9833, 9836, 9940 
9700-9719, 9729, 9768, 9827-9831, 9834, 9837, 9948 
9650-9667 
9740-9742 
9750-9758 
9590-9591, 9596, 9727, 9760, 9800-9801, 9805, 9820, 
9832, 9835, 9860, 9960, 9970, 9975, 9989 
9140 
8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-
9110, 9260-9365, 9380-9539 
8000-8005 
Adapted from “International rules for multiple primary cancers (ICD-0 third edition)”[52] 
The SPC may also be classified as synchronous or metachronous, according to time interval 
between the FPC and the SPC. The most frequently adopted criteria classifies the SPC as 
synchronous if the difference between the FPC and SPC was less than two months; metachronous 
SPC are those diagnosed at two months of follow-up of the FPC or posteriorly [54]. Although less 
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frequently, some studies adopted three, six or twelve months as the cutoff to classify synchronous 
and metachronous SPC.  
 
5.2.2.2. Frequency of SPC 
Information from the Eurocare-4 collaborative study using data from 69 European cancer 
registries, during the period 1995–1999, revealed that 6.3% of the incident cancer cases were SPC, 
ranging from 0.4% in the Naples registry (Italy) to 12.9% in the Icelandic registry [14]. The most 
frequent localizations of the SPC were colorectal (15.1%), lung (13.4%), female breast (11.5%) and 
prostate (10.3%), which corresponded to high incidence localizations when the overall cancer 
incidence is considered [14].  
Reports in USA using data from the National Cancer Institute’s (NCI) Surveillance, Epidemiology, 
and End Results Program (SEER), showed that 18% of the newly diagnosed cancers in 2007 were 
SPC [55]. Prostate (16.9%), female breast (15.6%), colorectal (14.2%) and urinary bladder (9.6%) 
cancers were the most frequent FPC topographies among cancer survivors that developed a SPC, 
corresponding to localizations with high frequency and survival [55]. 
 
5.2.2.3. Etiology of SPC 
According to the model proposed by Travis et al. [16], SPC can reflect host factors (high- and low-
penetrant genetic modifications), lifestyle environmental exposures and late consequences of FPC 
treatment (figure 12).  
The contribution of genetics to the etiology of SPC is complex and characterized by the penetrance 
of individual genetic variants and how these are modified by interaction with other risk factors for 
SPC. Some syndromic cancers are associated with nonmalignant phenotypes that identify 
individuals at increased risk, such as Fanconi anemia or Cowden disease, whereas others exhibit 
only malignant phenotypes, such as BRCA1- and/or BRCA2-related breast and/or ovarian cancer or 
Li Fraumeni syndrome [56]. Some syndromes are autosomal dominant (e.g., Li Fraumeni syndrome 
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and Cowden disease); others are autosomal recessive (e.g., Fanconi anemia, Bloom syndrome, and 
xeroderma pigmentosum). Usually they are most frequently observed in familiar setting, and the 
major susceptibility genes for many of these syndromes have already been identified. Although 
hereditary susceptibility explains only a small proportion of all second cancers, an increased risk of 
primary tumors arising in multiple sites is a distinguishing feature of kindreds carrying germline 
genetic predispositions and can provide unique insights into underlying mechanisms [56]. 
Figure 12 – Schematic illustration of risk factors for SPC 
 
Reproduced from Travis LB et al. [16]  
The overall burden of the risk of SPC associated with the common hereditary breast and colon 
cancer syndromes is remarkable, since they are frequent cancer localizations with good survival 
[16, 37], and 5% – 10 % may be caused by genetic factors [57]. The hereditary breast cancer 
survivors have a two to fivefold increased risk of developing cancers of the ovary, thyroid, and 
connective tissue, due to syndromic association of these tumors with inherited mutations of 
BRCA1, BRCA2, PTEN, and p53 [57]. By far the largest cumulative risk of a secondary cancer in 
BRCA mutation carriers is associated with cancer in the contralateral breast, which may reach a risk 
of 29.5% at 10 years [58]. The Breast Cancer Linkage Consortium [59] also documented threefold 
to fivefold increased risks of subsequent cancers of prostate, pancreas, gallbladder, stomach, skin 
(melanoma), and uterus in BRCA2 mutation carriers and twofold increased risks of prostate and 
pancreas cancer in BRCA1 mutation carriers [59-61].  
Familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC) are 
frequent inherited colorectal cancer syndromes. FAP has an incidence of 1 in 6000-13000, with 
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autosomal-dominant transmission and 100% penetrance [62]. It is characterized by the presence of 
100 or more adenomatous polyps in the colon. Colorectal cancer invariably occurs by 40–50 years 
of age unless prophylactic colectomy is performed [63]. FAP is also associated with colorectal, 
gastric, periampullary, small intestinal and thyroid cancers. HNPCC or Lynch II syndrome is the 
most frequent form of hereditary colorectal cancer, accounting for 6–10% of all colorectal cancers 
[63]. Synchronous and metachronous colorectal cancers are common, with most occurring 
proximal to the splenic flexure [63]. Lynch II syndrome is frequently associated with endometrial 
and ovarian cancers. Turcot syndrome is a combination of colonic polyps and a CNS neoplasm. In 
Turcot syndrome, medulloblastoma is usually associated with FAP, and glioblastoma is associated 
with HNPCC [62]. 
Although the cancer genetic syndromes that were previously described correspond to those most 
frequently associated with the total burden of SPC, Li Fraumeni, multiple endocrine neoplasia 
(MEN 1 and MEN 2), neurofibromatosis and von Hippel–Lindau (VHL) syndromes are other 
frequent cancer hereditary syndromes which predispose the individuals with the genetic 
alterations to a higher risk of developing several tumors. 
However, high-penetrance mutations in cancer susceptibility genes make only a small contribution 
to the SPC burden, owing to their low frequency [15]. The prevailing model is that genetic risk of 
both first and subsequent primary cancers is defined by the cumulative effect of multiple low-
penetrance and intermediate-penetrance risk alleles for cancer, where each individual genetic 
variant confers a modest increase in risk, but which collectively increase risk substantially when co-
inherited in an individual [15].  
Although there are scarce data evaluating the contribution of certain lifestyle factors (for example, 
diet, dietary supplements, physical activity, weight management, and sun exposure) to SPC 
development, for alcohol and tobacco consumption there is enough evidence suggesting their role 
as risk factors. 
Smoking increases the risk of several cancer types, mainly lung and esophagus, and is regarded as 
the cause of 25–30% of all deaths from cancer and 87% from lung cancer [64]. Tobacco smoke is 
proved to contain carcinogenic mutagens and alters a number of cell signaling pathways 
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predominantly by activation of nuclear transcription factor (NF‑κB) that induces tumorigenesis, via 
inflammation and other gene products [21]. 
The causal association between drinking alcohol and cancer development has been definitely 
established to oral, esophageal, liver and other head and neck cancers [21]. Although with a lower 
level of evidence, there is data demonstrating the carcinogenic role of alcohol in breast, colon and 
rectal cancers [21]. Several works have documented that there is a dose-response relationship 
between alcohol consumption level and cancer risk. The carcinogenic mechanisms associated with 
alcohol consumption are not yet completely understood. Among hypotheses proposed to explain 
the increased cancer risk are: a) a carcinogenic effect of chemicals other than ethanol present in 
alcoholic beverages (such as N-nitrosamines); b) a solvent action which facilitates absorption of 
other carcinogens; c) a carcinogenic role for acetaldehyde, the major metabolite of ethanol [65]. 
Alcohol drinking and tobacco smoking show a synergistic interaction in the etiology of cancers of 
the oral cavity, pharynx, larynx and oesophagus [21]. 
Consumption of high‑caloric and fatty food often combined with a sedentary lifestyle and hence 
energy imbalance, increases the risk of colon, breast, prostate, endometrial and other cancers [21]. 
Chronic infections, such as those with hepatitis B and C viruses, human papilloma viruses or 
Helicobacter pylori, are well‑known risk factors for specific cancers, and it was estimated that 
almost 18% of neoplasms are attributable to an infection [66, 67]. 
Another risk factor for development of SPC is the treatment of the FPC. A USA nationwide study 
using the SEER registries concluded that cancer treatment may only cause a minor proportion of all 
SPC when all adult-onset cancers are considered together (a noticeably larger role was observed 
among survivors of childhood cancer); however, in long-term survivors of certain adult onset 
cancers (for example, Hodgkin lymphoma), SPC are one of the most common causes of death [10].  
Radiotherapy is used to treat over 50% of patients with cancer, either as definitive, adjuvant or 
palliative treatment, resulting in an improvement in disease control, overall survival, and quality of 
life [15]. In a SEER study, the attributable risk of SPC related to radiotherapy ranged from 4% to 
24%, being especially evident among survivors of testicular seminoma [68]. The majority of 
radiotherapy-related SPC are solid tumors that frequently arise within or near irradiated fields and 
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are associated with latency periods of at least 5–10 years, with risk varying by age at exposure and 
attained age [15]. 
Among chemotherapy-associated SPC, a substantial amount of data has been published about 
therapy-related myeloid neoplasms, which are now classified as a distinct disease entity by World 
Health Organization (WHO) [15]. Several classes of chemotherapeutic agents have been associated 
with therapy-related myeloid neoplasms, including alkylating agents, topoisomerase II inhibitors 
and antimetabolites [69]. Tamoxifen is used as an adjuvant therapy in women with estrogen-
receptor (ER)-positive breast cancer, with an associated reduction in breast cancer recurrence and 
increased survival. However, studies have also demonstrated a two to four-fold increased risk of 
endometrial cancer after treatment with tamoxifen, especially among post-menopausal women 
[70]. Survivors of haematopoietic stem-cell transplantation (HSCT) are at increased risk of 
developing a SPC, mainly myeloid neoplasms and lymphoproliferative disorders, as well as solid 
tumors in young survivors [15]. 
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5.3. Social and economic burden 
Beside the comorbidities and the late-effects of cancer and its treatment on the physical and 
mental health status of the cancer patients, the social and economic burden of survivorship is also 
a matter of concern to the patients and to the society.  
 
5.3.1. Patients 
Several studies have demonstrated the profound financial consequences of a cancer diagnosis [71]. 
The cost of cancer diagnosis and treatment can present a barrier to obtaining high-quality care and 
adequate screening for cancer recurrence or SPC, which may result in worse survival [72]. Even for 
patients with insurance in the North American model and for European survivors with national 
health system support, out-of-pocket expenses associated with cancer treatment may still be 
substantial and lead to delay in treatment, noncompliance, exhaustion of savings, and personal 
bankruptcy [72, 73]. Moreover, these expenses often have a disproportionate effect on those with 
lower incomes [71]. 
In addition to its financial impact, increasing cancer care costs can affect the psychosocial well-
being of patients, as well as their ability to make optimal treatment decisions and implement them. 
Since these patients face a life-threatening illness they often have difficulty determining whether 
some treatment represents good value, as they perceive high-cost treatments to be more valuable 
than the other ones [74]. These patients may feel pressure to fight the battle against cancer at any 
cost, and they and their families may subjugate financial concerns to medical ones [71]. 
The cancer diagnosis may also represent a relevant financial burden for the patients due to 
changes in their employment status as well as in their families [11]. A recent meta-analysis of 36 
studies, predominantly from the USA and Europe, found that cancer survivors were 37% more 
likely to be unemployed compared with healthy controls [75].  In addition, only 60 % of individuals 
(on average) who are diagnosed with cancer have returned to work 1–2 years following cancer 
treatment [76]. This is problematic as many individuals who experience cancer may still be in the 
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prime of their working lives, and if unable to return to work, pose significant cost to the health care 
system and financial losses at the individual, family, and societal levels. 
Roelen et al. [77] demonstrated that, 2 years after a cancer diagnosis, the highest percentage of 
patients who had fully returned to work were those who had female genital cancer, male genital 
cancer and skin cancer. The lowest percentage of patients returning to work was observed among 
those with breast, lung and gastrointestinal tumors [77].  
 
5.3.2. Society 
Cancer is a major economic expenditure for all developed countries and the ability to deliver 
affordable care is becoming challenging. The total costs of cancer care in the USA were estimated 
to be more than 124 billion dollars for 2010, representing roughly 5% of total health-care spending 
[78]. The UK National Health System (NHS) reports that total cancer spending was 5.9 billion 
pounds in 2009–10, representing 5.6% of total health spending for the year [72]. Despite diverse 
health-care systems, the USA figure is remarkably consistent with data (2004) from Europe, 
Canada, Australia, and New Zealand, where cancer costs as a percentage of total health-care 
spending ranged from 4.1% in the Netherlands to 7% in Sweden [72]. In Japan, cancer costs 
accounted for a slightly higher percentage of total health-care spending, at 9.3% in 2004 [72]. Data 
from 2006 revealed that in Portugal, the cancer care expenditures were 565 million euros, 
corresponding to 3.9% of total health-care spending [79]. 
The issue that concerns economists and policy makers is not just the amount of money currently 
spent on health care, but also the rate of increase in spending. Data from the USA revealed that 
total spending on cancer is estimated to have grown from 27 billion dollars in 1990 to 90 billion 
dollars in 2008. It is projected to reach 157 billion dollars by 2020, roughly a 600% increase in 30 
years [78]. This trend of rising spending with cancer care is justified by a higher number of patients 
to be treated (as addressed in the previous chapters) but also to an increase in the cost to treat an 
individual patient. The latter is driven by innovation in cancer diagnostic and treatment 
procedures, overutilization of resources such as routine surveillance studies that have no evidence 
to support them, and also by futile disease-directed care provided in the last weeks of life, that has 
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financial consequences for the patient’s family and to the society, compromising the patient’s 
quality of life without a meaningful increase in overall survival [72]. 
Beyond the direct costs of cancer to individuals and health-care budgets, the economic and 
societal effect of cancer on family income and overall productivity is large, though not widely 
acknowledged in economic discussions of health-care expenditure. In Europe, the indirect costs of 
cancer in terms of lost productivity are estimated to be around 30% higher than the direct costs 
associated cancer treatments [72]. Although many European countries have employment 
discrimination laws and employment regulation to support disabled people, there is no legislation 
for chronically sick people. Therefore, many patients with cancer are permanently lost to the labor 
market, who could return to their jobs if given a chance and the time to overcome their disease. As 
a consequence, the financial effect of cancer in terms of social costs and reduced productivity is 
evident. Furthermore, vulnerable groups — such as people in poverty, migrants, ethnic minority 
groups, and disabled or elderly people — are often more affected by cancer in the economic and 
social domains, because their environment is less capable of compensating the strains of a cancer 
diagnosis [72]. 
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6. Aims 
The worldwide growing number of cancer survivors with the associated health and socio-economic 
burden, demands an accurate epidemiologic characterization within different settings, as well as a 
continuous monitoring of the evolving trends. Therefore, this thesis aimed to contribute to a better 
understanding of the epidemiology of cancer survivorship in Portugal, during the last decade. 
The main research question was applied, through the following specific objectives: 
1. To assess cancer survivors’ health status, use of healthcare resources and socio-economic 
conditions, in Portugal; 
2. To compare the frequency of exposure to environmental risk factors for chronic diseases 
between cancer survivors and individuals with no previous cancer diagnosis, within a 
Portuguese cohort; 
3. To estimate the dynamics of SPC incidence in a population-based cohort of cancer survivors 
from North Portugal;  
4. To quantify and characterize the SPC identified among the incident cancer cases from North 
Portugal, and to describe their survival according to the characteristics of the FPC. 
The methods and results are presented in each of the following papers: 
Paper I. Health status, use of healthcare, and socio-economic implications of cancer survivorship in 
Portugal: results from the Fourth National Health Survey. 
Paper II. Health-related behaviours in the EpiPorto study: cancer survivors versus participants with 
no cancer history.  
Paper III. Incidence of second primary cancers in North Portugal – a population-based study. 
Paper IV. Frequency and survival of second primary cancers in North Portugal – a population-based 
assessment. 
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Abstract  
Purpose: 
Longitudinal studies are needed to characterize the burden of second primary malignancies among 
cancer survivors. Therefore, we quantified the incidence rate and cumulative incidence of second 
primary cancers (SPC) and standardized incidence ratios (SIR) in a population-based cohort of 
subjects diagnosed with a first primary cancer (FPC). 
Methods:  
We evaluated a cohort of cancer patients from the Portuguese North Region Cancer Registry 
(RORENO), with the first diagnosis in 2000-2003 (n=39451), to estimate the incidence rate and 
cumulative incidence of SPC and standardized incidence ratios (SIR), for different periods of follow-
up, up to five years; SPC were defined according to the International Association of Cancer 
Registries and the International Agency for Research on Cancer guidelines. 
Results:  
The incidence rate of SPC was more than 5-fold higher in the first two months of follow-up than in 
the period between two months and five years (metachronous SPC), across which the incidence 
rates were relatively stable. Cancer survivors had an overall higher incidence rate of cancer than 
the general population (SIR=1.31; 95% CI: 1.25-1.38), although that difference faded when only 
metachronous SPC were considered (SIR=1.02; 95% CI: 0.96-1.08). Cancer incidence rates were 
higher among female lung FPC survivors and lower in prostate FPC cancer survivors than in the 
general population. The 5-year cumulative risk of developing a metachronous SPC was 3.0%, and 
reached nearly 5.0% among patients with FPC associated with lower risk of death. 
 
Conclusions:  
Cancer survivors had higher incident rates of cancer that the general population, especially due to 
diagnoses in the first months following the FPC. Nevertheless, after this period SPC remain 
frequent events among cancer survivors. 
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Implications for Cancer Survivors 
SPC constitute an important dimension of the burden of cancer survivorship, and this needs to be 
taken into account when defining strategies for surveillance, prevention and counseling. 
 
 
Key Words: Neoplasms, Second Primary; Population-based cancer registry; Incidence; Mortality. 
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Introduction 
The increasing number of incident cases of cancer [1] and the improvements in survival [2] have 
been contributing for a growing population of subjects with a previous diagnosis of cancer. It was 
estimated that in 2012 there were more than 32 million cancer survivors worldwide [3]; these 
subjects have an increased risk of several adverse health events and use of health resources [4], 
including the recurrence of the first primary cancer (FPC), cardiovascular diseases or second 
primary cancers (SPC) [5].  
The occurrence of SPC is mostly related to genetic characteristics, persistence of deleterious 
environmental exposures and late effects of FPC treatment [6]. Recognizing frequent FPC-SPC pairs 
can also be a useful starting point for investigating possible shared etiologies and mechanisms of 
carcinogenesis. Quantifying and characterizing the risk of second malignancies can have important 
implications for surveillance, prevention and counseling.  
SPC represented 16.0 % of all incident cancer cases in USA (2003) [5], 6.3% in Europe (1995-1999) 
[7] and 3.8% in North Portugal (2000-2003) [8]. These differences in the frequency of SPC reflect 
the heterogeneous distribution of cancer incidence and survival across settings, as well as the 
distinct sensitivity of population-based cancer registries with different operating times for 
detecting SPC in cross-sectional analyses [7]. A longitudinal assessment is expected to contribute 
for more accurate estimates, and a better understanding of the burden of SPC, by providing more 
clinically relevant measures of incidence. 
Therefore, we followed during five years a population-based cohort of cancer survivors to estimate 
incidence rates of SPC and corresponding standardized incidence ratios (SIR), which reflect the 
dynamics of SPC diagnosis and their relation with the expected cancer incidence in the general 
population. Cumulative incidences of SPC were computed to quantify the absolute risk of cancer 
survivors being diagnosed with another primary cancer. 
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Methods 
Study population and design 
We conducted a cohort analysis based on the North Region Cancer Registry (RORENO). This 
population-based cancer registry (RORENO) was set up in 1988 and covers the whole northern 
region of Portugal, corresponding to approximately 3.3 million inhabitants, which is nearly one-
third of the Portuguese population. 
All cases of cancer, other than skin non-melanoma, registered in the period 2000-2003, were 
followed for five years, until the diagnosis of a new primary cancer or until death, whichever 
occurred first; the vital status of the cancer patients was assessed through the National Health 
System database. 
Tumor topography and morphology were classified according to the International Classification of 
Diseases for Oncology, Third Edition (ICD-O-3) categories, and then recoded to the International 
Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10).  
 
Definition of multiple primary cancers (MPC) 
To define MPC we followed the guidelines proposed by the International Association of Cancer 
Registries (IACR) and the International Agency for Research on Cancer (IARC) [9]. Briefly, these 
criteria consider primary cancers those that originally developed in an organ or tissue, not being an 
extension, a recurrence or a metastasis. Different morphologies (even with a same topography) or 
dissimilar topographies should be regarded as MPC, regardless of the time between the diagnoses, 
unless they correspond to systemic cancers, which are considered the same cancer. 
Whenever more than two primary cancers were observed in the same patient, only the second 
primary cancer (SPC) was considered; third and subsequent primary cancers were disregarded for 
the present analysis. 
We classified the SPC as synchronous when diagnosed within two months of the corresponding 
FPC [10]. 
Papers 85 
 
Statistical analysis 
Person-years at risk (PYAR) among people diagnosed with a FPC was calculated as the time from 
the diagnosis of the FPC until five years of follow-up, date of death or date of diagnosis of a SPC, 
whichever came first.  
The incidence rate of SPC was computed for different periods (“0m to < 2m” – from the diagnosis 
until less than two months of follow-up; “≥2m to < 12m” – from two months until less than 12 
months of follow-up; “≥12 to ≤60m” – from 12 to 60 months of follow-up) since the diagnosis of 
the FPC, by dividing the incident cases of SPC by the PYAR within each time interval. Incidence 
rates were estimated also for women and men, and for the most frequent types of FPC. 
Standardised incidence ratios (SIRs) and corresponding 95% confidence intervals (95% CI), derived 
from the Poisson distribution, were computed to evaluate age-adjusted ratios of cancer incidence 
rates between cancer survivors and the general population. The SIRs were calculated dividing the 
observed number of SPC by the expected number of cancer cases in the same period of time, if the 
cancer incidence rates in the general population had been observed among cancer survivors. The 
latter were estimated multiplying the PYAR among cancer survivors by the sex- and age group-
specific cancer incidence rates observed in the general population of North Portugal in 2006 [11]. 
We computed the cumulative incidences of metachronous SPC and all cause of death for up to five 
years, stratified by sex and the most frequent types of FPC. Cumulative incidences were calculated 
dividing the observed number of cases of SPC or deaths until each period of analysis (2, 6, 12, 24, 
36, 48 and 60 months of follow-up) by the total number of survivors in the beginning of the study.  
All analyses were conducted using STATA®, version 9.2 (StataCorp LP, College Station, Texas, USA).  
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Results 
Among the 39451 patients with a FPC in 2000-2003, a total of 1589 SPC were observed in the first 
five years after the diagnosis of the FPC (120473 PYAR), from which 417 (26.2%) were diagnosed 
within the first two months after the FPC (synchronous tumors), 281 (17.7%) between more than 
two months and less than one year, and 891 (56.1%) between one and five years. 
A total of 61.0% of the SPC were observed among men and 56.6% in subjects aged 65 or more 
years. Regarding the distribution according to the most common groups of SPC, in relation with the 
observed for FPC diagnosed in 2000-2003, during the 5-year follow-up there was a lower 
proportion of SPC of the female breast (6.8% vs. 12.4%), prostate (8.1% vs. 11.9%) and stomach 
(9.2% vs. 11.1%), and a higher proportion of cancer of the colon and rectum (13.3% vs. 10.0% and 
7.9% vs. 5.7%, respectively), lung (10.7% vs. 7.9%) and bladder (6.2% vs. 5.0%) (Table 1). 
 
Incidence rate of SPC and SIR  
Overall, the incidence rate of SPC was more than 5-fold higher in the first two months of follow-up 
than in the period between two months and five years, across which the incidence rates were 
relatively stable. However, the differences between the 0m to <2m and the ≥2m to ≤60m periods 
were greater among the individuals with stomach, colon, rectum and lung FPC than among those 
with breast, prostate or bladder FPC (figure 1). 
The incidence rates observed among cancer survivors was more than 30% higher than the 
expected (SIR=1.31; 95% CI: 1.25-1.38), especially among women (SIR women=1.73; 95% CI: 1.60-
1.88 vs. SIR men=1.13; 95% CI: 1.06-1.21). This higher number of observed cases was mainly 
identified during the first two months of follow-up (synchronous SPC), and when this period was 
excluded from the analyzes the SIR were much lower (SIR=1.02, 95% CI: 0.96-1.08; SIR 
women=1.28, 95% CI: 1.17-1.41; SIR men=0.91, 95% CI: 0.85-0.98).  
During the first two months of follow-up the SIR were higher, both among women (SIR=10.22; 95% 
CI: 8.8-11.8) and men (SIR=4.86; 95% CI: 4.3-5.5); the results were similar for the most frequent 
topographies of FPC (figures 2 and 3).  
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The incidence rate among female survivors was higher than in the general population across the 
≥2m to <12m (SIR=1.37; 95% CI: 1.13-1.67) and the ≥12m to ≤60m (SIR=1.26; 95% CI: 1.13-1.40) 
follow-up intervals (figure 2). For men, the incidence rates were similar to those observed in the 
general population in the same periods (≥2m to <12m, SIR=0.91, 95% CI: 0.78-1.06; ≥12m to ≤60m, 
SIR=0.91, 95% CI: 0.84-0.99) (figure 3). 
Among women, the SIR was lower in the ≥2m to <12m period for those with a breast FPC 
(SIR=0.36; 95% CI: 0.17-0.76). Those with a lung FPC were more likely to develop a SPC during the 
≥12m to ≤60 period after the diagnosis of the FPC (SIR=3.00; 95% CI: 1.47-6.11). Among men, 
prostate cancer survivors showed a lower incidence rate of cancer than the general population in 
the ≥2m to <12m (SIR=0.52; 95% CI: 0.37-0.74) and ≥12m to ≤60m (SIR=0.67; 95% CI: 0.58-0.78) 
follow-up intervals. After the first two months of follow-up, there were no statistically significant 
differences in the cancer incidence rate between the general population and the cancer survivors 
with other FPC (figures 2 and 3). 
 
Cumulative incidence of SPC and death  
The 5-year cumulative incidence of SPC was 3.0% (women: 2.5%; men: 3.4%) and the risk of death 
in the same period was 46.1% (women: 38.8%; men: 52.1%) (figure 4 and appendix 1).  
Women with FPC of the colon or bladder had the highest 5-year risk of developing a SPC, 4.0% and 
3.6%, respectively, along with a 5-year cumulative risk of death among the lowest (colon: 46.2%; 
bladder: 37.8%). Those with lung and stomach FPC had some of the lowest 5-year risk of 
developing a SPC, 2.5% and 1.7%, respectively, and the highest 5-year risk of death (lung: 83.2%; 
stomach: 62.0%). Although the female breast cancer survivors had the lowest 5-year risk of death 
(19.4%), the 5-year risk of developing a SPC was also among the lowest (2.2%) (figure 5 and 
appendix 1).  
Men with prostate and bladder FPC had the highest 5-year cumulative incidence of SPC, 5.5% and 
4.5%, respectively, and were among those with the lowest 5-year risk of death (prostate: 25.0%; 
bladder: 35.2%). Subjects with a lung or a stomach FPC had the lowest 5-year risk of a SPC, 1.2% 
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and 2.7%, respectively, and were among those with highest 5-year risk of death (lung: 87.8%; 
stomach: 67.3%) (figure 5).  
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Table 1 – Characteristics of the study cohort. 
Total First primary cancer (FPC) Second primary cancer (SPC) 
 N % N % 
Sex     
Males 21694 55.0 970 61.0 
Females 17757 45.0 619 39.0 
Age at first diagnosis     
0-14 307 0.8 4 0.3 
15-49 years 7356 18.6 213 13.4 
50-64 years 11539 29.2 472 29.7 
65 years and over 20249 51.3 900 56.6 
Follow-up interval     
0 - < 2 months n.a.  417 26.2 
≥ 2 - < 12 months n.a.  281 17.7 
≥ 12 - < 60 months n.a.  891 56.1 
Topography     
Stomach (C16) 4382 11.1 146 9.2 
Colon (C18) 3955 10.0 211 13.3 
Rectum (C19 & C20) 2240 5.7 125 7.9 
Lung (C34) 3136 7.9 170 10.7 
Bladder (C67) 1977 5.0 99 6.2 
Female Breast (C50) 4894 12.4 108 6.8 
Prostate (C61) 4696 11.9 128 8.1 
Other 14171 35.9 602 37.9 
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Figure 1 – Trends in the incidence rates of second primary cancers (SPC) since the diagnosis of the corresponding first 
primary cancers (FPC). 
 
Incidence rates were estimated and represented for the following intervals: “0 - < 2 months”; “≥ 2 - < 6 months”; “≥ 6 - < 12 months”; “≥ 12 - < 24 
months”; “ ≥ 24 - < 36 months”; “ ≥ 36 - < 48 months”; “ ≥ 48 - < 60 months”  
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Figure 2 – Standardized incidence ratios (SIR) and 95% confidence intervals (95% CI) for the diagnosis of a second 
primary cancer, according to the first primary cancer and follow-up time since its diagnosis, among women. 
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Figure 3 – Standardized incidence ratios (SIR) and 95% confidence intervals (95% CI) for the diagnosis of a second 
primary cancer, according to the first primary cancer and follow-up time since its diagnosis, among men. 
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Figure 4 – Cumulative risk of death and incidence of second primary cancers (SPC), among women and men. 
 
 
Cumulative risks of death were estimated and represented for the following intervals: “0 - < 2 months”; “≥ 2 - < 6 months”; “≥ 6 - < 12 months”; “≥ 12 
- < 24 months”; “ ≥ 24 - < 36 months”; “ ≥ 36 - < 48 months”; “ ≥ 48 - < 60 months”; 
Cumulative incidences of SPC were estimated and represented for the following intervals: “≥ 2 - < 6 months”; “≥ 6 - < 12 months”; “≥ 12 - < 24 
months”; “ ≥ 24 - < 36 months”; “ ≥ 36 - < 48 months”; “ ≥ 48 - < 60 months”. 
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Figure 5 – Cumulative risk of death and incidence of second primary cancers (SPC), for the most frequent topographies 
of the first primary cancers, among women and men. 
 
Cumulative risks of death were estimated and represented for the following intervals: “0 - < 2 months”; “≥ 2 - < 6 months”; “≥ 6 - < 12 months”; “≥ 
12 - < 24 months”; “ ≥ 24 - < 36 months”; “ ≥ 36 - < 48 months”; “ ≥ 48 - < 60 months”; 
Cumulative incidences of SPC were estimated and represented for the following intervals: “≥ 2 - < 6 months”; “≥ 6 - < 12 months”; “≥ 12 - < 24 
months”; “ ≥ 24 - < 36 months”; “ ≥ 36 - < 48 months”; “ ≥ 48 - < 60 months”. 
0
.1
.2
.3
C
u
m
u
la
ti
v
e
 i
n
c
id
e
n
c
e
 o
f 
S
P
C
0
.2
.4
.6
.8
1
C
u
m
u
la
ti
v
e
 r
is
k
 o
f 
d
e
a
th
0 5 10 15 20 25 30 35 40 45 50 55 60
Time interval (months)
Stomach FPC (C16) - Men
0
.1
.2
.3
C
u
m
u
la
ti
v
e
 i
n
c
id
e
n
c
e
 o
f 
S
P
C
0
.2
.4
.6
.8
1
C
u
m
u
la
ti
v
e
 r
is
k
 o
f 
d
e
a
th
0 5 10 15 20 25 30 35 40 45 50 55 60
Time interval (months)
Stomach FPC (C16) - Women
0
.1
.2
.3
C
u
m
u
la
ti
v
e
 i
n
c
id
e
n
c
e
 o
f 
S
P
C
0
.2
.4
.6
.8
1
C
u
m
u
la
ti
v
e
 r
is
k
 o
f 
d
e
a
th
0 5 10 15 20 25 30 35 40 45 50 55 60
Time interval (months)
Colon FPC (C18) - Men
0
.1
.2
.3
C
u
m
u
la
ti
v
e
 i
n
c
id
e
n
c
e
 o
f 
S
P
C
0
.2
.4
.6
.8
1
C
u
m
u
la
ti
v
e
 r
is
k
 o
f 
d
e
a
th
0 5 10 15 20 25 30 35 40 45 50 55 60
Time interval (months)
Colon FPC (C18) - Women
0
.1
.2
.3
C
u
m
u
la
ti
v
e
 i
n
c
id
e
n
c
e
 o
f 
S
P
C
0
.2
.4
.6
.8
1
C
u
m
u
la
ti
v
e
 r
is
k
 o
f 
d
e
a
th
0 5 10 15 20 25 30 35 40 45 50 55 60
Time interval (months)
Rectum FPC (C19 & C20) - Men
0
.1
.2
.3
C
u
m
u
la
ti
v
e
 i
n
c
id
e
n
c
e
 o
f 
S
P
C
0
.2
.4
.6
.8
1
C
u
m
u
la
ti
v
e
 r
is
k
 o
f 
d
e
a
th
0 5 10 15 20 25 30 35 40 45 50 55 60
Time interval (months)
Rectum FPC (C19 & C20) - Women
0
.1
.2
.3
C
u
m
u
la
ti
v
e
 i
n
c
id
e
n
c
e
 o
f 
S
P
C
0
.2
.4
.6
.8
1
C
u
m
u
la
ti
v
e
 r
is
k
 o
f 
d
e
a
th
0 5 10 15 20 25 30 35 40 45 50 55 60
Time interval (months)
Lung FPC (C34) - Men
0
.1
.2
.3
C
u
m
u
la
ti
v
e
 i
n
c
id
e
n
c
e
 o
f 
S
P
C
0
.2
.4
.6
.8
1
C
u
m
u
la
ti
v
e
 r
is
k
 o
f 
d
e
a
th
0 5 10 15 20 25 30 35 40 45 50 55 60
Time interval (months)
Lung FPC (C34) - Women
0
.1
.2
.3
C
u
m
u
la
ti
v
e
 i
n
c
id
e
n
c
e
 o
f 
S
P
C
0
.2
.4
.6
.8
1
C
u
m
u
la
ti
v
e
 r
is
k
 o
f 
d
e
a
th
0 5 10 15 20 25 30 35 40 45 50 55 60
Time interval (months)
Bladder FPC (C67) - Men
0
.1
.2
.3
C
u
m
u
la
ti
v
e
 i
n
c
id
e
n
c
e
 o
f 
S
P
C
0
.2
.4
.6
.8
1
C
u
m
u
la
ti
v
e
 r
is
k
 o
f 
d
e
a
th
0 5 10 15 20 25 30 35 40 45 50 55 60
Time interval (months)
Bladder FPC (C67) - Women
0
.1
.2
.3
C
u
m
u
la
ti
v
e
 i
n
c
id
e
n
c
e
 o
f 
S
P
C
0
.2
.4
.6
.8
1
C
u
m
u
la
ti
v
e
 r
is
k
 o
f 
d
e
a
th
0 5 10 15 20 25 30 35 40 45 50 55 60
Time interval (months)
Female Breast FPC (C50)
0
.1
.2
.3
C
u
m
u
la
ti
v
e
 i
n
c
id
e
n
c
e
 o
f 
S
P
C
0
.2
.4
.6
.8
1
C
u
m
u
la
ti
v
e
 r
is
k
 o
f 
d
e
a
th
0 5 10 15 20 25 30 35 40 45 50 55 60
Time interval (months)
Prostate FPC (C61)
Papers 95 
 
Discussion 
Cancer survivors had an overall higher incidence rate of cancer than the general population of 
North Portugal, although that difference fades when only metachronous SPC are considered. The 
5-year cumulative risk of developing a SPC was 3.0%, and reached nearly 5.0% among patients with 
FPC associated with lower risk of death. 
The incidence rates of cancer were approximately 30% higher among cancer survivors, but similar 
to the observed in the general population when only the metachronous SPC were considered. The 
latter result is in agreement with a previous Finish study (SIR=0.99; 95% CI: 0.95-1.03) [12], 
whereas higher incidence rates of metachronous SPC were observed in Australia (SIR=1.27; 95% CI: 
1.25-1.29) [13], France (SIR=1.36; 95% CI: 1.35-1.38) [14], Japan (SIR=1.21; 95% CI: 1.19-1.23) [15] 
and USA (SIR=1.14; 95% CI: 1.14-1.15) [5], and lower rates were reported in Danish (SIR=0.91; 95% 
CI: 0.89-0.93) [16], UK (SIR=0.77; 95% CI: 0.75-0.79) [17] and Italian (SIR=0.93; 95% CI: 0.90-0.96) 
[18] studies. The heterogeneity of these results may reflect different patterns of cancer risk across 
populations and periods analysed, as well as the use of distinct definitions of SPC and synchronous 
tumours (intervals ranging from two months up to one year after the diagnosis of the FPC) and 
differences in the length of follow-up.  
Including synchronous SPC in the analyses allowed the comparison of incidence rates since the 
diagnosis of the FPC, which is seldom presented in other population-based studies [18], and the 
assessment of the effect of diagnosis anticipation in the incidence rates throughout the follow-up. 
In our study, more than one quarter of the SPC were synchronous tumors, reflecting the strong 
influence of common diagnostic and staging procedures performed during the clinical 
management of the FPC [19, 20] which contributed to an increased number of SPC diagnoses that 
otherwise would had not been identified soon after the diagnosis of the FPC. Since the FPC 
topographies with the highest incidence rates of SPC in the first two months corresponded to the 
lowest incident rates in the remaining 58 months of analysis, excluding the synchronous SPC might 
have contributed to an underestimation of the incidence rates after the first two months. This 
tendency for anticipation of the diagnosis of a SPC had already been identified in previous studies, 
where 20–30% of all SPC diagnosed in the first five years were identified within two months of the 
incidence date of the FPC [16, 18]. This phenomenon is analogous to the expected trend of the 
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incidence rate after a screening test, with a strong increase at the beginning (synchronous FPC), 
when prevalent cases are identified through anticipation of cancer diagnosis, followed by a 
decrease due to the lack of diagnosis of cancers already identified; afterwards a smooth slope of 
further increase until the usual incidence levels are reached again [21]. One example that 
illustrates the impact of excluding a high number of synchronous tumors in the quantification of 
metachronous SIR, was observed in the UK study [17], which reported lower SIR due to considering 
one of the largest synchronous periods (12 months).  
Several reports had documented that cancer survivors with a more recent diagnosis had a higher 
SIR of SPC than those diagnosed in earlier years [13, 15]. Although the reasons for those 
differences are not yet completely understood, cancer screening has been increasing during the 
past decades [22] and is more frequent among cancer survivors than the general population [23], 
which may result in higher SPC incidence rates in more recent years. 
Prostate cancer survivors had lower incidence rate of cancer than the general population, when 
analysing the whole follow-up period, in accordance to what was observed in other settings [5, 13, 
18]. A possible explanation for those findings is the high proportion of prostate cancers diagnosed 
by screening, which is more likely among individuals with higher educational and socio-economic 
status, and consequently with a healthier profile than the general population [24, 25]. 
Several studies have documented higher metachronous cancer incidence rates among female 
breast cancer survivors than in general population [5, 13-15], essentially due to tighter medical 
surveillance [20], a strong link between hormonal-related cancers [26] and a genetic predisposition 
(such as BRCA1 and BRCA2 syndromes) [27, 28]. However, in our study the rates in female breast 
cancer survivors were similar to the observed in general population; a plausible explanation for this 
discrepancy is the high proportion (22%) of synchronous SPC that we observed in breast cancer 
survivors, reflecting the anticipation of cancer diagnoses. When considering both synchronous and 
metachronous SPC, the observed SIR was 1.09 (95% CI: 0.91-1.29), which is closer to the observed 
in other studies [5]. Additionally, since a high proportion of female breast cancers are diagnosed by 
screening and women adhering to screening tend to be more educated than the general 
population [29], we may hypothesize that a large proportion of these female cancer survivors had 
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a healthier behaviour than the general population and, consequently, a lower incidence rate of a 
SPC. 
Women with a lung FPC had a higher cancer incidence rate than the general population, when 
considering the entire follow-up period, although among men there were no significant 
differences. A lower competing risk of death among women than in men with lung cancer [30] may 
contribute to the differences observed. However, since in Portugal women are at an earlier stage 
of the tobacco epidemic than men [31, 32], this may reflect mostly a more pronounced contrast 
between women with lung cancer and those from the general population regarding the exposure 
to risk factors such as smoking.  
To our knowledge, this was the first study to estimate the 5-year cumulative risk of developing a 
subsequent cancer among cancer survivors in Portugal. The 5-year cumulative incidence estimates 
were lower than those from the SEER, which ranged between 2.8% and 8.9%, respectively for lung 
and bladder FPC [5].  However, our results show that in North Portugal, as in other settings, SPC 
should be regarded as a problem commonly encountered in routine medical practice rather than a 
rare and unusual event to be described in case reports. Moreover, data on the cumulative 
incidences of SPC provides local clinicians with a benchmark to estimate the probability of cancer 
survivors developing another cancer within five years. 
Despite the strengths of using data from a population-based cancer registry, constituting an 
important piece of information for understanding the burden of SPC in North Portugal, some 
limitations need to be discussed. We only presented the overall SIR of SPC across the most 
frequent FPC, due to the low number of SPC in strata of less frequent FPC, precluding the 
identification of frequent FPC-SPC pairs, which are a useful starting point for investigating possible 
shared etiologies and mechanisms of carcinogenesis; this may be improved in future studies with 
larger samples. Survival is already high for several cancers, and a longer follow-up is needed for a 
more comprehensive understanding of the burden of SPC among cancer survivors. The 
completeness of registration of SPC may be higher than for FPC because cancer survivors have 
contacted with the cancer registry sources when the FPC was identified, which could contribute to 
an overestimation of SIR; however, the completeness of the registry is high [33], and this is not 
expected to have a major impact in the SIR estimates. On the other hand, in patients already being 
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followed a new primary cancer may be confused with recurrence, remaining unregistered; this is 
more likely to have occurred, depending on the procedures implemented in each source of data 
for the registry, contributing to an underestimation of the number of SPC. 
In conclusion, cancer survivors had higher incident rates of cancer that the general population, 
especially due to diagnoses in the first months following the FPC. Nevertheless, after this period 
SPC remain frequent events among cancer survivors, and constitute an important dimension of the 
burden of cancer survivorship. This needs to be taken into account when defining strategies for 
surveillance, prevention and counseling. 
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7. General discussion 
The present thesis provides an assessment of different dimensions of the burden of cancer 
survivorship in Portugal. We evaluated the health-status, the utilization of healthcare resources 
and the socio-economic condition among CS, concurrently with their exposure to risk factors for 
chronic diseases. Additionally, we assessed the dynamics of SPC incidence within the increasing 
number of survivors and the weight of secondary tumors among the incident cancer cases. Since 
each specific topic was addressed in the individual discussion of the four articles, along this general 
discussion we intend to integrate our main findings and to further discuss their public-health 
implications. 
Measuring the frequency of cancer survivors in Portugal is an important step through the 
assessment of the burden associated with cancer survivorship, since the public health relevance of 
the results obtained from the evaluation of the other outcomes is dependent of the dimension of 
the problem within the population. Although there are data from the GLOBOCAN estimating the 5-
year cancer prevalence [6], the latter underestimates the real number of cancer survivors, because 
it does not consider those with more than five years of follow-up, which are progressively more 
frequent due to higher survival rates. In Portugal, according to our results from the Fourth National 
Health Survey (2005-2006), there were approximately 220 000 cancer survivors, corresponding to 
2.2% of the entire population. Eight years later, this frequency is expected to be higher due to the 
increasing trends observed for cancer incidence (age-standardized incidence rate raised from 198.0 
per 100 000 in 2001 to 225.5 per 100 000 in 2007) and the better survival rates among the most 
frequent topographies [5-year age-standardized survival rates (1995-1999 to 2005-2009): lung 
(10.4% to 12.8%), colon (48.8% to 60.3%), breast (74.9% to 83.4%) and prostate (81.3% to 89.4%)] 
[80]. 
 As the number of cancer survivors is estimated to continue rising, the concerns about their health-
status, socio-economic situation and health-related behaviors become increasingly meaningful. 
Our results from the national survey showed that cancer survivors reported a worse perceived 
health-status and higher levels of short-term incapacity. We expect those individuals to have a 
poorer quality of life and had suffered changes in their employment status, as observed in other 
settings [11, 81-83]. A recent meta-analysis demonstrated that the unemployment rate among 
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cancer survivors is approximately 37% higher than the general population [75], which helps to 
elucidate the lower levels of family income after the cancer diagnosis that we found in our study. 
These results, together with the reported higher levels of health-related expenditures, may explain 
the long-term financial difficulties that we observed in our survey. Therefore, policy makers should 
consider setting up effective supportive programs to help the most socially disadvantaged cancer 
survivors, with the perspective of minimizing the financial difficulties and their negative impact in 
the quality of life and in the disease survival [72], namely through multidisciplinary interventions to 
enhance return-to-work rates [84]. 
Another important domain associated with cancer survivorship is the higher risk of comorbidities 
and new primary cancers development in comparison with the general population, which can 
result from the persistence of unhealthy lifestyle behaviors, or the maintenance of their effects, 
among other factors [13]. Therefore, locale-specific data characterizing modifiable health-related 
behaviors within cancer survivors and comparing them with the general population is useful to 
support health promotion activities in particular settings. The second study of this thesis, using 
data from an adult cohort representative of a city (Porto) in North Portugal, showed that the 
distribution of exposures to each of the most important risk factors for cancer and other chronic 
diseases among cancer survivors, tended to be similar to the observed in the subgroup of the 
general population with lower risk of cancer. Nevertheless, a high prevalence of risk factors for 
chronic diseases and a joint exposure to a large number of risk factors was observed within cancer 
survivors, showing that there is still an ample scope for these populations benefiting from lifestyle 
changes, which must be encouraged by clinicians and considered pertinent by public-health stake 
holders. 
The need to establish health promotion interventions in order to minimize the incidence of SPC 
among cancer survivors becomes increasingly meaningful, as this fearsome event is turning 
dramatically more frequent [55]. In the third and fourth studies of this thesis, we assessed the 
frequency of SPC in North Portugal, concurrently with a description of the overall survival among 
the individuals with more than one tumor, as other important domains of the cancer survivorship. 
The results showed that cancer survivors had an approximately 30% higher incidence rate of 
cancer than the general population, although that difference faded when only metachronous SPC 
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were considered. The incidence rate of SPC was more than 5-fold higher in the first two months of 
follow-up than in the period between two months and five years, reflecting the strong influence of 
common diagnostic and staging procedures, as suggested by the high frequency of gastro-
intestinal and genito-urinary synchronous FPC-SPC pairs documented in the fourth study. 
Moreover, 3% of the patients with a FPC had a metachronous SPC diagnosed within five years, and 
the probability of having a SPC was nearly 5% among patients with a FPC with expectedly lower risk 
of death.  
At a clinical level, these results highlight SPC as a problem increasingly encountered in routine 
medical practice rather than a rare and unusual event to be described in case reports. Additionally, 
they show there is a meaningful scope of benefit from encouraging the change of deleterious 
lifestyle behaviors among cancer survivors, in accordance with some results from the fourth study, 
which showed a high proportion of patients with lung SPC that had had previous bladder, head & 
neck or larynx cancers, illustrating the essential role of smoking as a main risk factor for both the 
FPC and the SPC. Besides cancer prevention, early diagnosis should also be a matter of concern 
among clinicians, by means of creating effective surveillance protocols, which might be based on 
data regarding the most frequent FPC-SPC pairs.  
Finally, the survival analyzes within the fourth study had also provided clinically relevant results, as 
they demonstrated that the contribution of the FPC for the overall survival of SPC patients tends to 
decrease as the time between the diagnoses increases.  
According to our fourth study, between 2002 and 2003, the proportion of SPC among the incident 
cancer cases registered in North Portugal was 4.0%, which was presumably underestimated due to 
the short operating time of the cancer registry [14]. Nowadays, it is expected that the real weight 
of the SPC among the new cancer cases diagnosed in North Portugal would be higher, owing to 
rising cancer incidence rates and survival improvement [80], in accordance with the proportions 
observed in other settings [18.0% in USA (2007) [55] and 6.3% in Europe (1995-1999) [14]]. The 
increasing number of SPC within the whole burden of cancer survivorship, highlight the public-
health relevance of this topic, because these individuals affected by more than one primary cancer 
are associated with an even higher risk of poorer physical and mental status [85], configuring a 
distinct subgroup among cancer survivors, to whom should be devoted increased attention.  
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Besides the rising number of SPC, other problems related to cancer survivors contribute to the 
increasing economic burden of this disease in almost every country [86]. In 2006, approximately 
565 million euros were spent for cancer treatment in Portugal, representing 3.9% of the national 
budget with healthcare [79]. Nevertheless, these estimates did not consider the higher levels of 
healthcare consumption, apart from cancer treatment, as we documented in the first study of this 
thesis. In accordance with data from other settings [87], our results showed that cancer survivors 
had a higher frequency of medical consultations, medication consumption and blood pressure and 
cholesterol assessments, although more pronounced during the first stages of the disease; 
therefore the overall weight in health budget due to cancer survivorship is expected to be even 
higher. Moreover, data from other settings [78] projected an increase of more than 30% with the 
cost of cancer during the next decade, not only due to population changes, but also to a rise in the 
price of cancer treatment programs. This scenario poses demanding challenges for the policy 
makers in the following years, concerning the planning and allocation of resources, especially 
during a context of economic and financial crisis in Europe. 
The results of this thesis highlight several challenges associated with survivorship, regarding not 
only economic issues, but also the health-status and quality of life of cancer survivors and their 
families. Primary care is well placed to address some of those challenges, as part of a 
comprehensive cancer care model that values many other important aspects of follow-up beyond 
the detection of recurrence, which has been classically considered the standard of care [88]. 
Primary-care physicians are well trained to deliver those different levels of survivorship care, 
because they are used to work with the physical, psychological, and social aspects of medicine, and 
are experts at delivering longitudinal chronic disease management [88]. Evidence suggests that 
comorbidities, prevention and screening are already well managed by the primary-care physicians 
in cancer patients and they can also give better support to their families [89, 90]. However, studies 
with patients have indicated they would welcome greater acknowledgement from their primary-
care physicians regarding their diagnosis and treatments and a more integrated support with the 
hospital care [91].  
The “survivorship care plans” (SCP’s), an individualized treatment summary and plan for ongoing 
care, was proposed as a valuable tool to aid in the management of these concerns, since it 
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contributes to a better coordination between health practitioners and ease their communication 
[13]. Many cancer treatment guidelines followed in different settings, suggest or recommend that 
every cancer patient must be provided with an SCP at the completion of their treatment [92]. 
However, although cancer survivors and their primary-care physicians were receptive to the 
concept of SCPs [93-95], the enthusiasm has been tempered by the realization that their 
implementation is resource-intensive [96-98] and the emerging evidence have only showed a few 
measurable benefits, such as higher levels of satisfaction among the survivors [92]. Thus, the long-
term effect of SCPs on psychosocial, oncological and resource outcomes should continue to be 
thoroughly evaluated, as it is unlikely that a unique model will suit all survivors, cancer centers or 
tumor types. Research addressing these variables in a consistent manner is awaited. 
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8. Conclusions 
The main conclusions of this thesis are: 
- In the middle of the last decade (2005-2006) the estimated number of cancer survivors was 
already high in Portugal (approximately 220 000), with worse health-status, higher level of 
incapacity, more financial difficulties, and greater usage of healthcare services than the general 
population. The cancer incidence and survival trends point for an increase of this burden during 
the next decades; 
 
- The distribution of the exposures to each of the most important risk factors for cancer and 
other chronic diseases among cancer survivors, tended to be similar to the observed in a 
subgroup of the general population with lower risk of cancer, despite there was still a high 
prevalence of risk factors for chronic diseases, demanding health promotion interventions in 
this specific population; 
 
- Cancer survivors had higher incident rates of cancer that the general population, especially due 
to diagnoses in the first months following the FPC. Nevertheless, after this period SPC 
diagnoses remained frequent events among cancer survivors, and constitute an important 
dimension of the burden of cancer survivorship. This needs to be taken into account when 
defining strategies for surveillance, prevention and counseling; 
 
- There was a considerable proportion of SPC (3.8%) in newly diagnosed cancer cases of North 
Portugal, in accordance with European estimates from cancer registries with similar operating 
time. The most common cancers in the general population were also frequent metachronous 
SPC, while the most frequent FPC were those with highest incidence and survival. The 
contribution of the FPC to the observed survival of SPC patients tended to decrease as the time 
between the diagnoses increases. 
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